Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Perlara announces $7.4M equity financing

Posted on: 01 Nov 17
Perlara announces $7.4M equity financing

PR Newswire

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2017

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2017 /PRNewswire/ -- Perlara, a drug discovery platform company partnering with highly motivated families and drug developers to cure diseases thought too rare to matter, today announced the closing of a $7.4M round of equity financing with participation by Pivotal Capital Alpha, Al-Hamra Group, Radical Investments, Homebrew Ventures, Haystack Fund and existing investors, including Y Combinator. Novartis participated in the financing under the terms of its research collaboration with Perlara.

The company has raised a total of $9.9M since inception in 2014. 

"With this funding we will be able to advance programs forward, discover novel lead compounds for our first three PerlQuest partners, and double our disease pipeline with the launch of six new PerlQuests," says Perlara founder and CEO Ethan Perlstein, PhD.

About Perlara
Perlara is a public benefit corporation working to develop cures for rare diseases and learn how genes work across diseases to map connections to common ailments. For general information and updates, please visit us at, connect with us at @PerlaraPBC on Twitter and at on Facebook, and learn specifically about PerlQuests at and


View original content with multimedia:

SOURCE Perlara

PR Newswire

Last updated on: 01/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.